Do rich markets lure biotechs away from low-cost remedies?

A pair of Canadian researchers has taken a close look at 78 small biotech companies operating in India, Brazil, China and South Africa and found that many are pursuing a host of new drugs and vaccines that would be affordable in the developing world. But there's a caveat: Many of these developers may be deflected from their mission if they're hijacked by companies more interested in treating the diseases that afflict the affluent in industrial countries. Article

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.